If oral paclitaxel (DHP107) is approved, how would you integrate it into your practice compared with weekly IV paclitaxel for HER2-negative metastatic breast cancer?

In the OPTIMAL study, oral paclitaxel showed non-inferior PFS and OS compared to IV paclitaxel when given as first-line chemotherapy for advanced disease on a day 1, 8, 15 schedule every 28 days. Different toxicities were observed. The oral formulation was associated with more neutropenia (including...